immatics.com (IMTX): Aggregate Business Value

Immatics Biotechnologies (IMTX) - corporate logo

The price history on the Immatics N.V. (IMTX) enterprise value chart on GURU.Markets is 653.34. Company management, recognized as an expert in developing T-cell therapies, is leveraging resources from global pharma behemoths. The business relies on AI systems and robotics to automate drug synthesis, reducing manual labor. The XPRESIDENT complex is currently being implemented, accelerating receptor selection through high-precision, 24/7 analysis.

IMTX (Immatics N.V.) Total Company Value history from 11/23/2025 to 10/28/2026

Immatics N.V. - analytical breakdowns and key metrics (IMTX)

- price and consensus price forecast:
Stock Quotes Immatics NV|IMTX - Consensus Target
- market capitalization data:
Market Value Immatics|IMTX - Real Price to Acquire Entire Company
- book capitalization data:
Equity per Share Immatics|IMTX - Company Book Value|Market-to-Book Ratio immatics.com|IMTX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Immatics N.V.|IMTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio immatics.com|IMTX - Company Debts|Debts to Book Value Immatics|IMTX - Company Long-Term Debt|Company Short-Term Debt Immatics
Fundamental valuation:Immatics NV (IMTX)
Original product of Immatics

Enterprise value determines the total market price for acquiring an asset. The dynamics of the business's market valuation visualize the current cost of capital in real time. This metric is calculated as the sum of market capitalization and net debt minus cash and cash equivalents. For Immatics N.V. (IMTX), this metric reflects the scale of investments in receptor bioengineering. The high potential of T-cell therapy directly impacts the fundamental value of the German developer.

Competitors of Immatics N.V. (IMTX)

IBRX - Real Price to Acquire Entire Company|Real Price to Acquire Entire Company Immunocore PLC IMCR|Janux Corp (JANX) - Aggregate Business Value|Real Price to Acquire Entire Company Arcus Biosciences, Inc.|ZYME (zymeworks.com) - Business Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Xencor Corp XNCR|Business Value Compass Therapeutics Corp (CMPX)|Replimune Group, Inc. - Enterprise Value|lyell.com - Real Price to Acquire Entire Company|IPHA (Innate Pharma) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)